FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation

May.07
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.

Key Takeaways

  • FDA announced the launch of Elsa 4.0 on May 6.
  • FDA consolidated more than 40 application and submission data sources, systems and portals into HALO.
  • HALO stands for Harmonized AI & Lifecycle Operations for Data.
  • Elsa 4.0 adds custom agents, document generation, data analysis and visualization, secure web search, voice-to-text and OCR.
  • FDA said Elsa is built in a FedRAMP High secure Google Cloud Platform environment and does not train on input data or data submitted by regulated industry.

2Firsts, May 7, 2026

 

According to the U.S. Food and Drug Administration, the agency announced major steps in its modernization initiative by launching Elsa 4.0 and consolidating multiple data sources, systems and portals.

 

FDA consolidated more than 40 data sources into HALO

 

FDA said Elsa 4.0 is a major upgrade to the agency’s internal AI tool and is available to all FDA staff, including scientific reviewers and investigators.

 

The agency also consolidated more than 40 disparate application and submission data sources, systems and portals across all FDA centers into a new platform called HALO, which stands for Harmonized AI & Lifecycle Operations for Data.

 

Elsa and HALO integration has begun

 

FDA said it has begun integrating HALO and Elsa so that staff can query data and build workflows without manually uploading documents within each chat. 

 

The agency said the HALO consolidation is expected to enable deeper deployment of AI capabilities within agency operations.

 

FDA commissioner said AI tools can reduce staff burden

 

FDA Commissioner Marty Makary said Elsa’s new capabilities position the agency as a leader in deploying AI tools that empower staff. He said removing tedious burdens allows staff to focus more on science and makes workflows more efficient and enjoyable.

 

Chief AI officer said Elsa will become the main entry point to FDA systems and data

 

FDA Chief AI Officer Jeremy Walsh said that with application and submission data sources, systems and portals consolidated into HALO and improvements in Elsa’s capabilities, Elsa will soon become the main entry point into FDA systems and data. 

 

He said FDA staff previously brought data to Elsa, while Elsa now sits on top of the agency’s data.

 

Elsa 1.0 was launched in June 2025

 

FDA said that since launching Elsa 1.0 in June 2025 ahead of schedule and under budget, the agency’s Office of Digital Transformation has continued to roll out improvements and pioneer new use cases with agency reviewers to help streamline operations.

 

Elsa 4.0 adds multiple features

 

According to FDA, new Elsa 4.0 features include custom agents, document generation, quantitative data analysis and visualization, including chart and graph creation, web search through a secure web access feature, voice-to-text dictation, conversion of scanned documents and images into searchable text through OCR, enhanced chat flexibility, and optimized search for key information in large document repositories.

 

FDA said Elsa does not train on input data

 

FDA said Elsa is built within a FedRAMP High secure Google Cloud Platform environment and does not train on input data or any data submitted by regulated industry, safeguarding sensitive research and data handled by FDA staff.

 

FDA said Elsa is not connected to the internet

 

The agency said Elsa’s enhanced search capability allows it to access refreshed secure web data in responses, but it is not connected to the internet.

 

FDA said staff are involved at every stage of the AI work process in Elsa, so that human subject matter experts verify all inputs, analytic processes and output implementation.

 

Image source: FDA

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Ulema Council (MUI) published Fatwa No. 131/2026 on November 9, declaring electronic cigarette use, production and trade haram under Islamic religious rules. The council urged the Industry Ministry to prohibit the issuance of vape industry permits and review licensing policies, while calling on the president and parliament to enact a comprehensive ban. On November 10, the Constitutional Court heard a challenge to provisions of the 2023 Health Law seeking a prohibition on vape production, importation, distribution and use. The Health Ministry said on November 11 it was studying stronger restrictions, including a possible ban on circulation, while industry association APVI called for tighter oversight rather than a total ban. Indonesia's Industry Ministry previously estimated the sector comprises about 200 companies, Rp31 trillion ($1.7 billion) in cumulative investment and approximately 100,000 supply-chain jobs. No nationwide statutory ban has been enacted.
Regulations
Nov.12
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's Ministry of Gender Equality and Family said on September 14 that it plans to designate unmanned e-cigarette stores as businesses where minors are prohibited from entering or working. Operators would be required to verify customers' ages and display notices restricting access by minors. The proposal is open for public comment through October 6. The move follows an April expansion of South Korea's statutory tobacco definition that brought products made with natural or synthetic nicotine under the Tobacco Business Act. Nicotine-free liquids and products using nicotine analogues such as 6-methylnicotine, however, remain an emerging regulatory issue.
Sep.21